ENLV Stock Summary and Trading Ideas (Enlivex Ltd. - | NASDAQ:ENLV)

Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.

Enlivex Ltd. - trades on the NASDAQ stock market under the symbol ENLV.

As of April 17, 2026, ENLV stock price declined to $0.86 with 404,928 million shares trading.

ENLV has a beta of -0.08, meaning it tends to be less sensitive to market movements. ENLV has a correlation of 0.00 to the broad based SPY ETF.

ENLV has a market cap of $205.69 million. This is considered a Small Cap stock.

In the last 3 years, ENLV traded as high as $4.59 and as low as $.66.

The top ETF exchange traded funds that ENLV belongs to (by Net Assets): IZRL, QQQS.

ENLV has underperformed the market in the last year with a price return of -0.1% while the SPY ETF gained +36.3%. ENLV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -8.6% and -9.7%, respectively, while the SPY returned +2.9% and +8.3%, respectively.

ENLV support price is $.83 and resistance is $.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENLV shares will trade within this expected range on the day.